A Phase 3 investigation designed t...
A Phase 3 investigation designed to evaluate the efficacy and safety of Metformin GR DepoMed's (Menlo Park, CA) augmented release formulation of the work in the treatment of pattern 2 diabetes, shows that the formulation achieves clinically meaningful and statistically significant reductions in hemoglobin A1C. The reductions were at
|